Sequana Medical NV (FRA:2SE) LT-Debt-to-Total-Asset: 0.05 (As of Jun. 2025)

What is Sequana Medical NV LT-Debt-to-Total-Asset?

Sequana Medical NV FRA:2SE 31 LT-Debt-to-Total-Asset is 0.05 as of Jun. 2025. GuruFocus rates FRA:2SE with a GF Score™ of 31/100 and a GF Value™ of €0.19. The stock has 12 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Sequana Medical NV's long-term debt to total assests ratio for the quarter that ended in Jun. 2025 was 0.05.

Sequana Medical NV's long-term debt to total assets ratio declined from Jun. 2024 (1.14) to Jun. 2025 (0.05). It may suggest that Sequana Medical NV is progressively becoming less dependent on debt to grow their business.

Sequana Medical NV (FRA:2SE) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Sequana Medical NV LT-Debt-to-Total-Asset Related Terms

Sequana Medical NV LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Sequana Medical NV's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sequana Medical NV LT-Debt-to-Total-Asset Chart

Sequana Medical NV Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.53

0.49

0.93

0.04

Sequana Medical NV Semi-Annual Data
	Dec14	Dec15	Dec16	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial														0.58	0.93	1.14	0.04	0.05

31GF Score

Sequana Medical NV FRA:2SE

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Sequana Medical NV LT-Debt-to-Total-Asset Calculation

Sequana Medical NV's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	0.358	/	9.944
	=	0.04

Sequana Medical NV's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2025 is calculated as

LT Debt to Total Assets (Q: Jun. 2025 )	=	Long-Term Debt & Capital Lease Obligation (Q: Jun. 2025 )	/	Total Assets (Q: Jun. 2025 )
	=	0.725	/	14.571
	=

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.05 mean?

Sequana Medical NV (FRA:2SE) has a LT-Debt-to-Total-Asset of 0.05 as of Jun. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Sequana Medical NV and its competitors.

Is Sequana Medical NV's LT-Debt-to-Total-Asset too high?

Sequana Medical NV's current LT-Debt-to-Total-Asset is 0.05. Overall, Sequana Medical NV has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.

How does Sequana Medical NV's LT-Debt-to-Total-Asset compare to ABT and SYK?

Sequana Medical NV's LT-Debt-to-Total-Asset of 0.05 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Medical Devices & Instruments company?

A good LT-Debt-to-Total-Asset depends on the Medical Devices & Instruments industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Sequana Medical NV and its competitors. Sequana Medical NV's current LT-Debt-to-Total-Asset is 0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Sequana Medical NV stock overvalued right now?

Sequana Medical NV (FRA:2SE) has a current LT-Debt-to-Total-Asset of 0.05. The stock's GF Value™ is €0.19, compared to a current price of €0.51 — trading 169.5% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.05. Sequana Medical NV's overall GF Score™ is 31/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Sequana Medical NV (FRA:2SE), the current LT-Debt-to-Total-Asset is 0.05 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sequana Medical NV (FRA:2SE) Overvalued in 2026?

Based on GuruFocus' analysis, Sequana Medical NV stock appears to be overvalued. The current stock price of €0.51 is trading 169.5% above its estimated GF Value™ of €0.19.

Key valuation signals for FRA:2SE:

LT-Debt-to-Total-Asset: 0.05
GF Value™: €0.19 vs. price of €0.51 (169.5% above fair value)
GF Score™: 31/100 with 12 warning signs

No single metric tells the full story. See the FRA:2SE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sequana Medical NV Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies XBRU:NYXH ABT SYK MDT BSX EW XTER:SHL GEHC DXCM XAMS:PHIA SZSE:300760 STE ZBH XSWX:SOON LSE:SN.PEN SHSE:688271 GMED TSE:7733 PODD

Other Exchanges 2SE:Germany SEQUA:Belgium

Address Kortrijksesteenweg 1112, bus 102, Sint-Denijs-Westrem, Ghent, BEL, 9051

Website https://www.sequanamedical.com

Sequana Medical NV is a commercial-stage medical device company focused on the development of treatment solutions for the management of fluid overload in liver disease, malignant ascites, and heart failure. The company's products include an alfa pump, which provides a treatment solution for the long-term management of liver refractory ascites and malignant ascites with safety, efficacy, and quality of life benefits demonstrated in multiple clinical studies. The company's geographical segments include Switzerland, Germany, the United Kingdom, France, and the Rest of the world, out of which Germany accounts for the majority of the revenue.

31GF Score

Get the complete analysis for FRA:2SE

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.51

Price

€0.19

GF Value

View FRA:2SE Analysis

See LT-Debt-to-Total-Asset data for all stocks →